The Cancer Genomics and Epigenetics Axis aims to elucidate the molecular mechanisms underlying cancer initiation, progression and therapeutic response by combining genomics, epigenetics and genetic engineering. The main objectives of the axis include the mapping of genetic and epigenetic alterations in various tumors using next-generation sequencing technologies; the identification of diagnostic and prognostic biomarkers; the identification of new therapeutic targets; and the development of targeted therapies, notably using epigenetic inhibitors and genetic engineering. This axis also explores interactions between the genome and the epigenome, while strengthening interactions with the Institute’s other research axes studying immunology, metabolism and cell signaling, in order to design combinatorial strategies for personalized treatments.

The Cancer Genomics and Epigenetics Axis contributes directly to IRIC’s mission by generating cutting-edge fundamental knowledge of the genetic and epigenetic mechanisms that play key roles in the development and progression of cancers (basic research for a better understanding of cancer). Through approaches such as epigenetic mapping and CRISPR genetic engineering, this axis accelerates the discovery of therapeutic targets and biomarkers that enable the development of personalized and more effective treatments (valorization, translational/clinical applications).

Axis leader: Geneviève Deblois

Primary affiliations : Sylvie Mader, Brian Wilhelm.

Secondary affiliations : Delphine Bouilly, David Knapp, Sébastien Lemieux, Julie Lessard, Claude Perreault, Philippe Roux, Guy Sauvageau, Pierre Thibault.